APA

Cortes J. E., Douglas Smith B., Wang E. S., Merchant A., Oehler V. G., Arellano M., DeAngelo D. J., Pollyea D. A., Sekeres M. A., Robak T., Ma W. W., Zeremski M., Naveed Shaik M., Douglas Laird A., O'Connell A., Chan G. & Schroeder M. A. (20190819). Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. : American journal of hematology.

Chicago

Cortes Jorge E, Douglas Smith B, Wang Eunice S, Merchant Akil, Oehler Vivian G, Arellano Martha, DeAngelo Daniel J, Pollyea Daniel A, Sekeres Mikkael A, Robak Tadeusz, Ma Weidong Wendy, Zeremski Mirjana, Naveed Shaik M, Douglas Laird A, O'Connell Ashleigh, Chan Geoffrey and Schroeder Mark A. 20190819. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. : American journal of hematology.

Harvard

Cortes J. E., Douglas Smith B., Wang E. S., Merchant A., Oehler V. G., Arellano M., DeAngelo D. J., Pollyea D. A., Sekeres M. A., Robak T., Ma W. W., Zeremski M., Naveed Shaik M., Douglas Laird A., O'Connell A., Chan G. and Schroeder M. A. (20190819). Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. : American journal of hematology.

MLA

Cortes Jorge E, Douglas Smith B, Wang Eunice S, Merchant Akil, Oehler Vivian G, Arellano Martha, DeAngelo Daniel J, Pollyea Daniel A, Sekeres Mikkael A, Robak Tadeusz, Ma Weidong Wendy, Zeremski Mirjana, Naveed Shaik M, Douglas Laird A, O'Connell Ashleigh, Chan Geoffrey and Schroeder Mark A. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. : American journal of hematology. 20190819.